Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for its primary biliary excretion rather than renal.
## Primary Indications
Type 2 diabetes mellitus (T2DM) to improve glycemic control as an adjunct to diet and exercise.
## Adult Dosing
5 mg orally once daily. May be taken with or without food.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients (under 18 years of age). Use is not recommended.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
## Contraindications
* History of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to linagliptin.
* Current use is not indicated for the treatment of Type 1 diabetes or diabetic ketoacidosis.
## Adverse Effects
* **Common:** Nasopharyngitis, increased risk of hypoglycemia when used with insulin or insulin secretagogues (e.g., sulfonylureas).
* **Serious:** Acute pancreatitis (discontinue if suspected), severe and disabling arthralgia, bullous pemphigoid, and hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** May decrease linagliptin efficacy. If co-administration is necessary, monitor glycemic control closely.
* **Insulin/Insulin Secretagogues:** Risk of hypoglycemia is increased; consider dose reduction of the secretagogue or insulin.
## Monitoring
* **HbA1c:** Perform at baseline and every 3 to 6 months.
* **Renal Function:** Not required due to primary biliary excretion, but recommended as part of routine diabetes care.
* **Clinical:** Monitor for signs/symptoms of pancreatitis (persistent, severe abdominal pain) and bullous pemphigoid (blistering or erosions).
## Clinical Pearls
* Linagliptin is the only DPP-4 inhibitor that does not require dose adjustments for renal failure, making it a favorable choice in patients with chronic kidney disease (CKD).
* Does not typically cause weight gain.
* If a dose is missed, instruct the patient to take it as soon as remembered, but do not take two doses on the same day.
***
**Educational Disclaimer:** This information is for educational purposes only. Always verify current prescribing information, clinical guidelines, and institutional protocols before prescribing or administering medication. Consult the primary manufacturer’s package insert for the most comprehensive and up-to-date data.
